Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance

Clinical trials have recently demonstrated the effectiveness of Pre-Exposure Prophylaxis (PrEP) in preventing HIV infection. Consequently, PrEP may soon be used for epidemic control. We model the dynamic interactions that will occur between treatment programs and potential PrEP interventions in resource-constrained countries. We determine the consequences for HIV transmission and drug resistance. We use response hypersurface modeling to predict the effect of PrEP on decreasing transmission as a function of effectiveness, adherence and coverage. We predict PrEP will increase need for second-line therapies (SLT) for treatment-naïve individuals, but could significantly decrease need for SLT for treatment-experienced individuals. If the rollout of PrEP is carefully planned it could increase the sustainability of treatment programs. If not, need for SLT could increase and the sustainability of treatment programs could be compromised. Our results show the optimal strategy for rolling out PrEP in resource-constrained countries is to begin around the “worst” treatment programs.

[1]  M. Kalish,et al.  Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United States , 2008, Journal of Clinical Microbiology.

[2]  J. Eron,et al.  Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[4]  Carel Pretorius,et al.  Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa , 2010, PloS one.

[5]  Robert J. Smith,et al.  Could disease-modifying HIV vaccines cause population-level perversity? , 2004, The Lancet. Infectious diseases.

[6]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[7]  A. Hatzakis,et al.  Natural history of HIV-1 infection. , 2000, Clinics in dermatology.

[8]  F. Ceccherini‐Silberstein,et al.  Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens , 2010, Journal of acquired immune deficiency syndromes.

[9]  Else Smith.  [Condom effectiveness in reducing heterosexual HIV transmission]. , 2002, Ugeskrift for laeger.

[10]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[11]  M. Hudgens,et al.  Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. , 2006, The Journal of infectious diseases.

[12]  M. Wainberg,et al.  HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture , 2006 .

[13]  Roy M. Anderson,et al.  Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings , 2007, PloS one.

[14]  Charles Poole,et al.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[15]  S. Kalichman,et al.  Recent multiple sexual partners and HIV transmission risks among people living with HIV/AIDS in Botswana , 2007, Sexually Transmitted Infections.

[16]  G. Box,et al.  Response Surfaces, Mixtures and Ridge Analyses , 2007 .

[17]  M. Hughes,et al.  Antiretroviral regimens in pregnancy and breast-feeding in Botswana. , 2010, The New England journal of medicine.

[18]  H. Jaffe,et al.  Pre-exposure prophylaxis for HIV infection: what if it works? , 2007, The Lancet.

[19]  Alessandro Cozzi-Lepri,et al.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.

[20]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[21]  V. Calvez,et al.  Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission , 2003, Antiviral therapy.

[22]  M. Wainberg.  The impact of the M184V substitution on drug resistance and viral fitness. , 2004, Expert review of anti-infective therapy.

[23]  Thomas Lengauer,et al.  Dynamics of NRTI resistance mutations during therapy interruption. , 2009, AIDS research and human retroviruses.

[24]  M. Wainberg,et al.  Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens , 2009, Journal of the International AIDS Society.

[25]  K. Hope.  Population mobility and multi-partner sex in Botswana: implications for the spread of HIV/AIDS. , 2001, African journal of reproductive health.

[26]  W. Heneine,et al.  Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. , 2011, Virology.

[27]  L. Shafer,et al.  HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda , 2007, AIDS.

[28]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[29]  Scaling up priority HIV / AIDS interventions in the health sector JUNE 2008 , 2008 .

[30]  V. DeGruttola,et al.  Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program , 2008, AIDS.

[31]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor , 2005, Nature Medicine.

[32]  M. Feinberg.  Changing the natural history of HIV disease , 1996, The Lancet.

[33]  H. Moffat,et al.  Two and a Half Years of Routine HIV Testing in Botswana , 2007, Journal of acquired immune deficiency syndromes.

[34]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[35]  Bikram Chakraborty,et al.  Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation , 2005, Journal of Clinical Microbiology.

[36]  Brett Williams,et al.  Relative risk of HIV infection among young men and women in a South African township , 2002, International journal of STD & AIDS.

[37]  S. Pinkerton,et al.  Updated estimates of condom effectiveness. , 1998, The Journal of the Association of Nurses in AIDS Care : JANAC.

[38]  W. Heneine,et al.  Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection , 2010, Science Translational Medicine.

[39]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[40]  Explore Configuring,et al.  A Simulation Study to , 2004 .

[41]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[42]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[43]  M. Wainberg,et al.  Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[44]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[45]  Marie-Claude Boily,et al.  Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. , 2009, The Lancet. Infectious diseases.

[46]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[47]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[48]  David K Plate,et al.  Evaluation and implementation of rapid HIV tests: the experience in 11 African countries. , 2007, AIDS research and human retroviruses.

[49]  C. Boucher,et al.  Implications of antiretroviral resistance on viral fitness , 2001, Current opinion in infectious diseases.

[50]  W. Heneine,et al.  Oral pre-exposure prophylaxis for HIV prevention. , 2010, Trends in pharmacological sciences.

[51]  Patrick S Sullivan,et al.  Number of casual male sexual partners and associated factors among men who have sex with men: Results from the National HIV Behavioral Surveillance system , 2011, BMC public health.

[52]  Sally Blower,et al.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis , 2010, Proceedings of the National Academy of Sciences.

[53]  Arthur W. Wetzel,et al.  Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) , 2011, PloS one.

[54]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[55]  Matthias Cavassini,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  B. Walker,et al.  Acute human immunodeficiency virus type 1 infection. , 1998, The New England journal of medicine.

[57]  Kishor Mandaliya,et al.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.

[58]  S. Karim,et al.  Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges , 2009 .

[59]  P. Vernazza,et al.  High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. , 1998, The Journal of infectious diseases.

[60]  M. Segal,et al.  Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.

[61]  C. Rouzioux,et al.  HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.

[62]  Michael Monsour,et al.  Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.

[63]  D. Stram,et al.  Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. , 1997, American journal of epidemiology.

[64]  C. Boucher,et al.  The risk of HIV drug resistance following implementation of pre-exposure prophylaxis , 2010, Current opinion in infectious diseases.

[65]  D. Richman,et al.  Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  N. Pedersen,et al.  Prophylactic and Therapeutic Benefits of Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) Administration to Newborn Macaques following Oral Inoculation with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA , 2000, Journal of Virology.

[67]  R. Gross,et al.  Antiretroviral Failure Despite High Levels of Adherence: Discordant Adherence-Response Relationship in Botswana , 2008, Journal of acquired immune deficiency syndromes.

[68]  C. Boucher,et al.  Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. , 2009, The Journal of infectious diseases.

[69]  S. Pinkerton,et al.  Effectiveness of condoms in preventing HIV transmission. , 1997, Social science & medicine.

[70]  J. Cherrington,et al.  Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. , 1999, The Journal of infectious diseases.

[71]  R. Hayes,et al.  Persisting with prevention: The importance of adherence for HIV prevention , 2008, Emerging themes in epidemiology.

[72]  M. Wainberg,et al.  Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. , 2004, The new microbiologica.

[73]  P. Cane.  Stability of transmitted drug-resistant HIV-1 species , 2005, Current opinion in infectious diseases.

[74]  D. Pillay,et al.  Long-Term Persistence of Primary Genotypic Resistance After HIV-1 Seroconversion , 2004, Journal of acquired immune deficiency syndromes.

[75]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[76]  J. Lawrence,et al.  Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity , 2011, PloS one.

[77]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[78]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[79]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[80]  C. Verhofstede,et al.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. , 1999, AIDS.

[81]  M. Boily,et al.  Efficacy dilution in randomized placebo-controlled vaginal microbicide trials , 2009, Emerging themes in epidemiology.

[82]  R. Chaisson,et al.  Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa , 2009, Journal of acquired immune deficiency syndromes.

[83]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[84]  Christian Laurent,et al.  Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients , 2011, AIDS.

[85]  J. Dik F. Habbema,et al.  The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study , 2008, PloS one.

[86]  K. White,et al.  Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations* , 2004, Journal of Biological Chemistry.

[87]  S. Blower,et al.  Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban–rural divide , 2006, Proceedings of the National Academy of Sciences.

[88]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[89]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[90]  M. Peeters,et al.  Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo , 2011, Journal of acquired immune deficiency syndromes.

[91]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[92]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[93]  W. Heneine,et al.  The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.

[94]  B. Brenner,et al.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. , 2009, HIV therapy.